KOSUNI KOREA
Korean News in English
News

Etoimidate: Classification as a Psychotropic Drug and Important Precautions

Published September 18, 2026 · 3 views
Etoimidate: Classification as a Psychotropic Drug and Important Precautions

Etoimidate's Classification as a Psychotropic Drug and Transition to Controlled Substance Status

Etoimidate is classified as a psychotropic drug, and will transition to controlled substance status effective February 13, 2026, when mandatory NIMS reporting requirements will be implemented. This measure follows concerns about misuse and illegal distribution, earning it the nickname 'the second Propofol' due to large-scale illegal trafficking incidents that have been uncovered.

Regulatory reforms are being introduced to strengthen psychotropic drug management, with similar regulations appearing in China as well. On October 14, 2024, discussions began about classifying Etoimidate, known as 'the controversial white anesthetic,' as a controlled substance.

Criminal Misuse and Medical Institution Abuse of Etoimidate

Etoimidate is classified as a psychotropic drug under current regulations while being pushed toward controlled substance status. It has gained the nickname 'zombie drug' due to its illegal distribution in e-cigarette form, and misuse within medical facilities has led to dermatology clinics transforming into drug injection sites.

On June 21, 2022, Yonhap News reported on criminal misuse cases of Etoimidate. On February 14, 2025, reports emerged expressing concerns from hospitals about staffing shortages due to the upcoming controlled substance classification. On March 16, 2026, YTN covered a case involving 'travel injections' that led to an investigation.

Medical Facility Inspections and Customs Border Controls

On June 23, 2026, Seoul City identified 15 medical facilities for inadequate handling of Etoimidate. This marks the first enforcement action following its classification as a controlled substance, highlighting serious management lapses at medical institutions.

The Customs Service has implemented border controls to prevent illegal sales. On September 19, 2019, individuals involved in the illegal sale of 'the second Propofol' Etoimidate received prison sentences, and on August 17, 2023, Medipos News recommended against using Etoimidate for sedation during endoscopic procedures.

Etoimidate's Composition and Circumstances of Criminal Misuse

Etoimidate is a psychotropic drug classified as a general anesthetic. It shares similar components with Propofol, beginning to be referred to as 'the second Propofol' starting June 21, 2022, when criminal misuse cases started emerging.

On August 13, 2025, individuals were arrested for distributing Etoimidate mixed into fish anesthetic liquid in Gangnam entertainment venues. This represents a typical case of illegal distribution through e-cigarettes, posing serious health risks to users.

In medical settings, there are ongoing discussions about whether classifying Etoimidate as a controlled substance is appropriate and whether regulatory reforms have been adequately implemented. Hospitals express concerns about staffing shortages related to management requirements.

Response Measures and Safety Information Following Controlled Substance Transition

Etoimidate will be classified as a controlled substance starting February 13, 2026, with mandatory NIMS (Psychotropic Drug Management System) reporting for medical facilities. Additional measures to prevent illegal distribution are necessary.

After identifying 15 medical institutions, Seoul City plans to strengthen management through education and supervision. The Customs Service is expanding enforcement against illegal sales alongside border controls.

The medical community continues to debate whether classifying Etoimidate as a controlled substance is appropriate and whether regulatory reforms have been sufficiently implemented. A case reported on August 13, 2025, involving the distribution of Etoimidate mixed into fish anesthetic liquid in Gangnam entertainment venues underscores the severity of misuse and illegal distribution within medical facilities.

Key Information to Verify

The classification as a psychotropic drug and transition to controlled substance status for Etoimidate is confirmed for February 13, 2026. This follows discussions initiated on October 14, 2024, about classifying the 'controversial white anesthetic' Etoimidate as a controlled substance.

Notable misuse cases include the 'travel injection' scandal where dermatology clinics became drug injection sites due to management lapses. On August 13, 2025, a case involving Etoimidate mixed into fish anesthetic liquid distributed in Gangnam entertainment venues also gained attention.

The September 19, 2019, prison sentence for illegal distribution was prior to Etoimidate's classification as a controlled substance. After this case, regulations were revised to push for its controlled substance designation.

에토미데이트 향정신의약품 분류와 주의사항 설명 이미지

Frequently Asked Questions

What type of psychotropic drug is Etoimidate?

Etoimidate is a psychotropic drug classified as a general anesthetic, containing components similar to Propofol. While used in medical settings for sedation and anesthesia, misuse can lead to serious health risks.

Why is Etoimidate referred to as 'the second Propofol'?

It is called 'the second Propofol' due to its similar components. However, before being classified as a controlled substance, it was managed less strictly as a psychotropic drug, leading to misuse and illegal distribution.

What impact will the transition to a controlled substance have on the medical community?

Medical facilities will be required to report through NIMS, raising concerns about staffing shortages. However, enhanced management is expected to improve user safety by preventing illegal distribution.

Frequently Asked Questions

Etoimidate is classified as a psychotropic drug and will transition to controlled substance status effective February 13, 2026, with mandatory NIMS reporting. This follows large-scale illegal distribution incidents that earned it the nickname 'the second Propofol' and led to serious health risks for users, also being referred to as the 'zombie drug.' Medical facilities have faced issues including dermatology clinics becoming drug injection sites due to misuse and management lapses, with 15 facilities identified by Seoul City. The Customs Service is implementing border controls to prevent illegal sales.

Despite a prison sentence case in 2019 for illegal distribution, Etoimidate remains at high risk for misuse and illegal distribution. Enhanced management through controlled substance classification will require greater collaboration between the medical community and government.

Read More Related Articles

You can view more articles on this topic in one place.

View Related Articles

FAQ

What type of psychotropic drug is Etoimidate?

Etoimidate is a psychotropic drug classified as a general anesthetic, containing components similar to Propofol. While used in medical settings for sedation and anesthesia, misuse can lead to serious health risks.

Why is Etoimidate referred to as 'the second Propofol'?

It is called 'the second Propofol' due to its similar components. However, before being classified as a controlled substance, it was managed less strictly as a psychotropic drug, leading to misuse and illegal distribution.

What impact will the transition to a controlled substance have on the medical community?

Medical facilities will be required to report through NIMS, raising concerns about staffing shortages. However, enhanced management is expected to improve user safety by preventing illegal distribution.

Korean Source

This article is an English localization of a Korean-language report from BlogScore. Original: 에토미데이트 향정신의약품 분류와 주의사항